|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
D5392NL0002 ARREST, NCT00246961
|
|
|
|
|
|
|
|
Last Modified: 1/15/2008  First Published: 8/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
ROCHE-BO16216 CWRU-030118, GENENTECH-H2223g, ROCHE-1100, ROCHE-B016216F, NCT00022672
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
any age
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
ZENECA-1033IL/0030 NCI-V96-1049
|
|
|
|
|
|
|
|
Last Modified: 7/18/2005  First Published: 7/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
Not specified
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
RPCI-DS-97-29 ZENECA-9238IL/0021, NCI-G98-1412
|
|
|
|
|
|
|
|
Last Modified: 8/28/2008  First Published: 1/26/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
Postmenopausal
|
|
|
|
NCI
|
|
|
|
NSABP-B-35 SWOG-NSABP-B-35, NCCTG-NSABP-B-35, ACOSOG-NSABP-B-35, NSABP-B-35, NCT00053898
|
|
|
|
|
|
|
|
Last Modified: 1/27/2005  First Published: 1/26/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 to 65
|
|
|
|
Other
|
|
|
|
FRE-FNCLCC-PACS-03/003 EU-20237, NCT00053911
|
|
|
|
|
|
|
|
Last Modified: 8/1/2008  First Published: 7/26/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
Postmenopausal
|
|
|
|
NCI, Other
|
|
|
|
CAN-NCIC-MA27 (COMPANION) NCCTG-MA27, CALGB-CAN-NCIC-MA27, ECOG-CAN-NCIC-MA27, SWOG-CAN-NCIC-MA27, NCIC-MA.27, NCT00066573, IBCSG-30-04, EUDRACT-2005-001893-28, MA27
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Supportive care, Treatment
|
|
|
|
Completed
|
|
|
|
Postmenopausal
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
D5392C00050 SABRE, NCT00082277
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
No age specified
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
CFEM345D2411 NCT00248170
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
No age specified
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
D6997L00002 9238SW/0001, FACT, NCT00256698
|
|
|
|